QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.108.145102v1 328/1/231    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Behm, D. J. Articles by Douglas, S. A. Search for Related Content PubMed PubMed Citation Articles by Behm, D. J. Articles by Douglas, S. A.

CARDIOVASCULAR

Epoxyeicosatrienoic Acids Function as Selective, Endogenous Antagonists of Native Thromboxane Receptors: Identification of a Novel Mechanism of Vasodilation

Metabolic Pathways Center of Excellence for Drug Discovery, GlaxoSmithKline, King of Prussia, Pennsylvania

Epoxy- and dihydroxy-eicosatrienoic acids (EETs and DHETs) are vasoactive cytochrome P450 metabolites of arachidonic acid. Interestingly, however, the mechanism(s) by which EETs/DHETs mediate smooth muscle relaxation remains unclear. In contrast to previous reports, where dilation was purportedly large-conductance Ca²⁺-activated K⁺ (BK_Ca) and/or transient receptor potential cation channel, subfamily V, member 4 (TRPV4) channel-mediated, 14,15-EET-induced vasodilation [reversal of contractile tone established with the thromboxane receptor (TP) agonist 15-hydroxy-11,9-(epoxymethano)prosta-5,13-dienoic acid (U-46619)] was unaltered in BK_Ca and TRPV4 knockout mouse isolated aortae compared with wild-type controls, indicating a significant BK_Ca/TRPV4-resistant mechanism. Whereas all EET and DHET regioisomers reversed U-46619 contraction in rat aortae and mouse mesenteric resistance arteries, these eicosanoids failed to alter phenylephrine-induced contraction, suggesting that they mediated dilation via a "TP-selective" mechanism. Competitive TP antagonism was also observed in nonvascular tissue, including rat fundus and tertiary bronchus, indicating that the effect is not specific to blood vessels. Such effects were TP-selective because 14,15-EET failed to inhibit "non-TP" prostanoid receptor-mediated function in multiple cell/tissue-based assays (K_b > 10 µM). In accordance, 14,15-EET inhibited specific [³H]7-(3-((2-((phenylamino)carbonyl)hydrazino)-methyl)-7-oxabicyclo(2.2.1)hept-2-yl)-5-heptenoic acid (SQ-29548) binding to human recombinant TP receptor, with a K_i value of 3.2 µM, and it showed weaker affinity for non-TP prostanoid receptors, including DP, FP, EP_1–4, and IP receptors (K_i values of 6.1, 5.3, 42.6, 19.7, 13.2, 20.2, and >25 µM, respectively) and no appreciable affinity (K_i values >10 µM) for a diverse array of pharmacologically distinct receptors, including the leukotriene receptors Cys-LT_1/2 and BLT₁. As such, EETs/DHETs represent a unique class of "endogenous" G protein-coupled receptor competitive antagonists, inducing vasodilation via direct TP inhibition. Thus, EETs/DHETs represent novel autoregulatory agents, directly modulating the actions of cyclooxygenase-derived eicosanoids following arachidonic acid mobilization.

Address correspondence to: David J. Behm, GlaxoSmithKline, 709 Swedeland Rd., King of Prussia, PA 19406-0939. E-mail: david.j.behm{at}gsk.com

This article has been cited by other articles:

				T. Pearson, A. Y. Warren, D. A. Barrett, and R. N. Khan Detection of EETs and HETE-generating cytochrome P-450 enzymes and the effects of their metabolites on myometrial and vascular function Am J Physiol Endocrinol Metab, September 1, 2009; 297(3): E647 - E656. [Abstract] [Full Text] [PDF]

				K. Schror Cyclooxygenase-2-Derived Prostaglandin F2{alpha}: An Endothelium-Derived Contractile Factor Acting Independently of Other Endothelium-Derived Contractile Factors via Vascular Thromboxane Receptors Circ. Res., January 30, 2009; 104(2): 141 - 143. [Full Text] [PDF]